uniQure Faces Investor Lawsuit Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: PRnewswire
- Lawsuit Update: Hagens Berman is updating its investigation into uniQure N.V. regarding a securities class action lawsuit for the period from September 24 to October 31, 2025, reminding investors to submit Lead Plaintiff applications by April 13, 2026, to represent others in the litigation.
- Serious FDA Allegations: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could negatively impact the company's reputation and future research prospects.
- Overview of Allegations: The class action, Scocco v. uniQure N.V., alleges that uniQure failed to disclose its interactions with the FDA and used a pivotal study design that was not approved, potentially leading investors to misjudge the company's future outlook.
- Whistleblower Incentives: Hagens Berman encourages individuals with insider information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially attracting more insiders to participate in the investigation and further impacting uniQure's legal situation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.260
Low
33.00
Averages
49.88
High
70.00
Current: 15.260
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Investor Lawsuit Reminder
- Lawsuit Update: Hagens Berman is updating its investigation into uniQure N.V. regarding a securities class action lawsuit for the period from September 24 to October 31, 2025, reminding investors to submit Lead Plaintiff applications by April 13, 2026, to represent others in the litigation.
- Serious FDA Allegations: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could negatively impact the company's reputation and future research prospects.
- Overview of Allegations: The class action, Scocco v. uniQure N.V., alleges that uniQure failed to disclose its interactions with the FDA and used a pivotal study design that was not approved, potentially leading investors to misjudge the company's future outlook.
- Whistleblower Incentives: Hagens Berman encourages individuals with insider information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially attracting more insiders to participate in the investigation and further impacting uniQure's legal situation.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. is facing a securities fraud class action lawsuit for material misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with investors able to seek lead plaintiff status by April 13, 2026, highlighting significant legal risks and potential financial repercussions for the company.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the timeline for its Biologics License Application (BLA) submission was unclear, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29, indicating a severe loss of market confidence in the company's prospects and potentially leading to diminished investor trust.
- Legal Action: Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, suggesting that the ongoing legal challenges may impact the company's future financing capabilities and market reputation, necessitating cautious investor responses.
- Uncertain Company Outlook: Throughout the lawsuit period, uniQure failed to adequately disclose the FDA approval status of its clinical trials, resulting in weakened investor confidence in its drug development, which could adversely affect future investment decisions and market performance.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Ethical Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially damaging the company's reputation in clinical trials.
- Legal Action: uniQure is facing a securities class action lawsuit alleging that it failed to disclose the lack of regulatory consensus with the FDA during the Class Period from September 24 to October 31, 2025, leading to a 49% stock drop on November 3, which resulted in significant investor losses.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, highlighting the legal and regulatory pressures on the company that may impact its future financing and market performance.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure revealed that the FDA was dissatisfied with the timeline for its BLA submission for AMT-130, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting a pessimistic market sentiment regarding the company's prospects.
- Investor Action Guidance: Affected uniQure investors must apply by April 13, 2026, to serve as lead plaintiffs in the class action, highlighting investor concerns over corporate governance and transparency in the wake of the lawsuit.
- Law Firm Credentials: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud litigation, having recovered over $25 billion for clients, demonstrating its strong capabilities and influence in investor protection efforts.
See More
uniQure Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against uniQure in the Southern District of New York on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, indicating significant legal challenges for the company.
- Allegations Overview: The complaint alleges that uniQure made materially false and misleading statements during the class period and failed to disclose critical adverse facts about its business operations, potentially leading to investor losses.
- FDA Approval Concerns: The lawsuit highlights that the design of uniQure's pivotal study was not fully approved by the FDA, and the company may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, impacting its market outlook.
- Investor Rights Protection: Investors are encouraged to apply by April 13, 2026, to be appointed as lead plaintiffs in the lawsuit, emphasizing the potential financial and reputational risks facing the company.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that they must file lead plaintiff applications by April 13, 2026, for shares purchased between September 24 and October 31, 2025, highlighting the growing concern among investors regarding potential legal risks associated with the company.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors about the likelihood of FDA accelerated approval for the drug AMT-130, thereby undermining investor confidence.
- Stock Price Plunge: Following the November 3, 2025 announcement that the FDA no longer deemed the data from AMT-130's studies adequate for BLA submission, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29 per share, reflecting a pessimistic outlook on the company's future prospects.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service to assist investors in understanding securities class action lawsuits and provides legal consultation to help recover losses incurred due to the company's alleged misconduct.
See More
uniQure Faces Investor Lawsuit Reminder
- Lawsuit Update: Hagens Berman is updating its investigation into uniQure N.V. regarding a securities class action lawsuit for the period from September 24 to October 31, 2025, reminding investors to submit Lead Plaintiff applications by April 13, 2026, to represent others in the litigation.
- Serious FDA Allegations: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could negatively impact the company's reputation and future research prospects.
- Overview of Allegations: The class action, Scocco v. uniQure N.V., alleges that uniQure failed to disclose its interactions with the FDA and used a pivotal study design that was not approved, potentially leading investors to misjudge the company's future outlook.
- Whistleblower Incentives: Hagens Berman encourages individuals with insider information to utilize the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, potentially attracting more insiders to participate in the investigation and further impacting uniQure's legal situation.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. is facing a securities fraud class action lawsuit for material misstatements regarding its Huntington's disease gene therapy drug during the period from September 24 to October 31, 2025, with investors able to seek lead plaintiff status by April 13, 2026, highlighting significant legal risks and potential financial repercussions for the company.
- Stock Price Plunge: Following the revelation on November 3, 2025, that the timeline for its Biologics License Application (BLA) submission was unclear, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29, indicating a severe loss of market confidence in the company's prospects and potentially leading to diminished investor trust.
- Legal Action: Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation, suggesting that the ongoing legal challenges may impact the company's future financing capabilities and market reputation, necessitating cautious investor responses.
- Uncertain Company Outlook: Throughout the lawsuit period, uniQure failed to adequately disclose the FDA approval status of its clinical trials, resulting in weakened investor confidence in its drug development, which could adversely affect future investment decisions and market performance.
See More
uniQure Faces Severe FDA Rebuke Amid Class Action Lawsuit
- FDA Criticism: An FDA official labeled uniQure's lead gene therapy candidate AMT-130 as a 'failed therapy' during a media call, accusing the company of making 'distorted or manipulated comparisons' in clinical studies, which could undermine investor confidence in the company's future prospects.
- Ethical Controversy: The FDA dismissed uniQure's ethical concerns regarding sham surgeries, clarifying that it did not request 'drilling holes' but rather 'one to three nicks in the scalp' under minimal anesthesia, potentially damaging the company's reputation in clinical trials.
- Legal Action: uniQure is facing a securities class action lawsuit alleging that it failed to disclose the lack of regulatory consensus with the FDA during the Class Period from September 24 to October 31, 2025, leading to a 49% stock drop on November 3, which resulted in significant investor losses.
- Critical Deadline: Investors must apply to be Lead Plaintiff by April 13, 2026, highlighting the legal and regulatory pressures on the company that may impact its future financing and market performance.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24 and October 31, 2025, indicating significant legal risks that could impact the company's stock price and market confidence.
- Stock Price Plunge: On November 3, 2025, uniQure revealed that the FDA was dissatisfied with the timeline for its BLA submission for AMT-130, causing its stock price to plummet from $67.69 to $34.29, a drop of over 49%, reflecting a pessimistic market sentiment regarding the company's prospects.
- Investor Action Guidance: Affected uniQure investors must apply by April 13, 2026, to serve as lead plaintiffs in the class action, highlighting investor concerns over corporate governance and transparency in the wake of the lawsuit.
- Law Firm Credentials: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud litigation, having recovered over $25 billion for clients, demonstrating its strong capabilities and influence in investor protection efforts.
See More
uniQure Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against uniQure in the Southern District of New York on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, indicating significant legal challenges for the company.
- Allegations Overview: The complaint alleges that uniQure made materially false and misleading statements during the class period and failed to disclose critical adverse facts about its business operations, potentially leading to investor losses.
- FDA Approval Concerns: The lawsuit highlights that the design of uniQure's pivotal study was not fully approved by the FDA, and the company may need to delay its Biologics License Application (BLA) timeline to conduct additional studies, impacting its market outlook.
- Investor Rights Protection: Investors are encouraged to apply by April 13, 2026, to be appointed as lead plaintiffs in the lawsuit, emphasizing the potential financial and reputational risks facing the company.
See More
uniQure Faces Securities Class Action Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds uniQure investors that they must file lead plaintiff applications by April 13, 2026, for shares purchased between September 24 and October 31, 2025, highlighting the growing concern among investors regarding potential legal risks associated with the company.
- Disclosure Violations: uniQure and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which misled investors about the likelihood of FDA accelerated approval for the drug AMT-130, thereby undermining investor confidence.
- Stock Price Plunge: Following the November 3, 2025 announcement that the FDA no longer deemed the data from AMT-130's studies adequate for BLA submission, uniQure's stock price plummeted by $33.40, or over 49%, from $67.69 to $34.29 per share, reflecting a pessimistic outlook on the company's future prospects.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service to assist investors in understanding securities class action lawsuits and provides legal consultation to help recover losses incurred due to the company's alleged misconduct.
See More
